Results 31 to 40 of about 20,028 (211)

Beyond Simple Mimicry: Next‐Generation Geometric Architectures and Future Paradigms in Small‐Molecule and Macrocyclic Peptidomimetics

Angewandte Chemie, EarlyView.
Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee, Sumin Son, Jeong Yeon Yoo, Ji Hyae Lee, Meehyun Chun, Seung Bum Park   +5 more
wiley   +2 more sources

Assessing the functional consequence of loss of function variants using electronic medical record & Large-Scale Genomics Consortium Efforts

Frontiers in Genetics, 2014
Estimates from large scale genome sequencing studies indicate that each human carries up to 20 genetic variants that are predicted to results in loss of function (LOF) of protein-coding genes.
Patrick eSleiman, Jonathan eBradfiled, Frank eMentch, Berta eAlmoguera, John eConnolly, Hakon eHakonarson   +5 more
doaj   +1 more source

Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus

Renal Failure, 2023
Purpose The purpose of this study was to investigate the association between serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and renal function impairment in type 2 diabetes mellitus (T2DM) patients.Methods PCSK9 levels were measured ...
Zhicai Feng, Xiangyu Liao, Hao Zhang, Juan Peng, Zhijun Huang, Bin Yi   +5 more
doaj   +1 more source

PCSK9 [PDF]

Circulation Research, 2014
Since the discovery of proprotein convertase subtilisin kexin 9 (PCSK9) in 2003, this PC has attracted a lot of attention from the scientific community and pharmaceutical companies. Secreted into the plasma by the liver, the proteinase K–like serine protease PCSK9 binds the low-density lipoprotein (LDL) receptor at the surface of hepatocytes, thereby ...
Nabil G, Seidah, Zuhier, Awan, Michel, Chrétien, Majambu, Mbikay   +3 more
openaire   +2 more sources

Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer

Frontiers in Oncology, 2021
BackgroundEsophageal cancer often appears as postoperative metastasis or recurrence after radical surgery. Although we had previously reported that serum programmed cell death ligand 1 (PD-L1) level correlated with the prognosis of esophageal cancer ...
Masaaki Ito, Takaki Hiwasa, Takaki Hiwasa, Yoko Oshima, Satoshi Yajima, Takashi Suzuki, Tatsuki Nanami, Makoto Sumazaki, Fumiaki Shiratori, Kimihiko Funahashi, Shu-Yang Li, Yasuo Iwadate, Hiroki Yamagata, Byambasteren Jambaljav, Minoru Takemoto, Minoru Takemoto, Koutaro Yokote, Hirotaka Takizawa, Hideaki Shimada, Hideaki Shimada   +19 more
doaj   +1 more source

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD) [PDF]

Advanced Pharmaceutical Bulletin, 2020
Proprotein convertase subtilisin/kexin type 9 (PCSK9), as a vital modulator of low-density lipoprotein cholesterol (LDL-C) , is raised in hepatocytes and released into plasma where it binds to LDL receptors (LDLR), leading to their cleavage.
Saeideh Sobati, Amir Shakouri, Mahdi Edalati, Daryoush Mohammadnejad, Reza Parvan, Javad Masoumi, Jalal Abdolalizadeh   +6 more
doaj   +1 more source

Regulation of PCSK9 During Oxidized LDL-Induced Foam Cell Formation in RAW264.7 Cells

Biology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is traditionally known for regulating plasma LDL cholesterol levels via LDL receptor degradation.
Md Sariful Islam Howlader, Manjusri Das, Surajit Hansda, Md Afjalus Siraj, Hiranmoy Das   +4 more
doaj   +1 more source

Elevated circulating PCSK9 level is associated with 28-day mortality in patients with sepsis: a prospective cohort study

BMC Emergency Medicine, 2023
Objectives Pro-protein convertase subtilisin/kexin 9 (PCSK9) decreases the clearance of the pathogenic lipids, supporting the potential role of PCSK9 in the prognosis of sepsis.
Yuanlu Shu, Ziwei Deng, Ye Deng, Jianliang Zhou, Jin Wang, Zhenxing Duan, Tao Jiang, Xiang Zhao, Zhihua Shi, Chengfeng Qiu   +9 more
doaj   +1 more source

PCSK9 deficiency alters brain lipid composition without affecting brain development and function

Frontiers in Molecular Neuroscience, 2023
PCSK9 induces lysosomal degradation of the low-density lipoprotein (LDL) receptor (LDLR) in the liver, hereby preventing removal of LDL cholesterol from the circulation.
Angela Pärn, Ditte Olsen, Jürgen Tuvikene, Jürgen Tuvikene, Mathias Kaas, Ekaterina Borisova, Ekaterina Borisova, Mesut Bilgin, Mie Elhauge, Joachim Vilstrup, Joachim Vilstrup, Peder Madsen, Peder Madsen, Mateusz C. Ambrozkiewicz, Roman U. Goz, Tõnis Timmusk, Tõnis Timmusk, Victor Tarabykin, Victor Tarabykin, Camilla Gustafsen, Camilla Gustafsen, Simon Glerup, Simon Glerup   +22 more
doaj   +1 more source

Association of high proprotein convertase subtilisin/kexin type 9 antibody level with poor prognosis in patients with diabetes: a prospective study

Scientific Reports, 2023
In addition to pathogenic autoantibodies, polyclonal autoantibodies with unknown physiological roles and pathogenicity are produced in the body. Moreover, serum antibodies against the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein, which ...
Hiroki Yamagata, Aiko Hayashi, Yoich Yoshida, Masaya Koshizaka, Shunichiro Onishi, Tomohiko Yoshida, Takaki Hiwasa, Minoru Takemoto   +7 more
doaj   +1 more source